Close

DLL-3

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

  • CAR-MA Vector Products

  • CAR-MA Cell Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Host:
  • Hinge:
  • TM:
  • ICD:
CAT Product Name Target Species Antibody Clone Host Hinge TM ICD Inquiry & Datasheet
CARMA-W1855 Anti-DLL-3 (Rovalpituzumab) ICD(CD147) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized IgG1 CD147 CD147   Add to Cart   Datasheet
CARMA-W1856 Anti-DLL-3 (Rovalpituzumab) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized CD8 CD8 CD86+FcγRI   Add to Cart   Datasheet
CARMA-W1857 Anti-DLL-3 (Rovalpituzumab) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized CD8 CD8 CD3ζ   Add to Cart   Datasheet
CARMA-W1858 Anti-DLL-3 (Rovalpituzumab) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized CD8 CD8 Megf10   Add to Cart   Datasheet
CARMA-W1859 Anti-DLL-3 (Rovalpituzumab) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized CD8 CD8 FcRɣ   Add to Cart   Datasheet
CARMA-W1860 Anti-DLL-3 (Rovalpituzumab) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 Human Rovalpituzumab Humanized CD8 CD8 FcRɣ+PI3K   Add to Cart   Datasheet
CARMA-W1861 Anti-DLL-3 (huSC16.13) ICD(CD147) CAR-MA Plasmid, pCDCAR1 Human huSC16.13 Humanized IgG1 CD147 CD147   Add to Cart   Datasheet
CARMA-W1862 Anti-DLL-3 (huSC16.13) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 Human huSC16.13 Humanized CD8 CD8 CD86+FcγRI   Add to Cart   Datasheet
CARMA-W1885 Anti-DLL-3 (huSC16.46) ICD(CD147) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized IgG1 CD147 CD147   Add to Cart   Datasheet
CARMA-W1886 Anti-DLL-3 (huSC16.46) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized CD8 CD8 CD86+FcγRI   Add to Cart   Datasheet
CARMA-W1887 Anti-DLL-3 (huSC16.46) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized CD8 CD8 CD3ζ   Add to Cart   Datasheet
CARMA-W1888 Anti-DLL-3 (huSC16.46) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized CD8 CD8 Megf10   Add to Cart   Datasheet
CARMA-W1889 Anti-DLL-3 (huSC16.46) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized CD8 CD8 FcRɣ   Add to Cart   Datasheet
CARMA-W1890 Anti-DLL-3 (huSC16.46) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 Human huSC16.46 Humanized CD8 CD8 FcRɣ+PI3K   Add to Cart   Datasheet
CARMA-W1891 Anti-DLL-3 (huSC16.15) ICD(CD147) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized IgG1 CD147 CD147   Add to Cart   Datasheet
CARMA-W1892 Anti-DLL-3 (huSC16.15) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized CD8 CD8 CD86+FcγRI   Add to Cart   Datasheet
CARMA-W1893 Anti-DLL-3 (huSC16.15) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized CD8 CD8 CD3ζ   Add to Cart   Datasheet
CARMA-W1894 Anti-DLL-3 (huSC16.15) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized CD8 CD8 Megf10   Add to Cart   Datasheet
CARMA-W1895 Anti-DLL-3 (huSC16.15) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized CD8 CD8 FcRɣ   Add to Cart   Datasheet
CARMA-W1896 Anti-DLL-3 (huSC16.15) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 Human huSC16.15 Humanized CD8 CD8 FcRɣ+PI3K   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.